Todd McAllister, PhD, is recognized as one of the visionaries driving the transformation of modern healthcare and is among the earliest architects of the field now known as Longevity Medicine. A scientist, entrepreneur, and systems thinker, his work has helped redefine healthcare from a reactive, disease-centered model to a proactive, data-driven discipline focused on extending healthspan, performance, and functional longevity. Over the past 25 years, Dr. McAllister has founded, scaled, and advised multiple companies at the forefront of transformative healthcare.
Dr. McAllister was the co-founder and CEO of Fountain Life, alongside Tony Robbins and Peter Diamandis. Fountain was one of the first companies globally to focus explicitly on proactive, prevention-based healthcare rather than episodic disease treatment. At Fountain Life, he designed and operationalized what has become the cornerstone of the longevity medicine model, formally organizing care around the foundational pillars of Precision Diagnostics, Performance Optimization, and Advanced Therapeutics. Today, this concept still defines the approach of almost every Longevity Medicine clinic and Fountain is widely credited as the company that started the movement to focus on healthspan rather than lifespan.
Following Fountain Life, Dr. McAllister partnered with ProMedica Health System, the 14th largest healthcare system in the United States with more than $10 billion in annual revenue, to build and operate the Icaria Longevity Center. This initiative embedded a proactive, prevention-based longevity platform within a traditional primary care system, demonstrating how advanced longevity concepts could be integrated into large-scale, legacy healthcare environments. This was a critical step in democratizing Longevity Medicine and ProMedica is seen as the first healthcare system to begin bringing the concept of proactive care to the masses.
Most recently, Dr. McAllister founded Skai Health, a network of concierge primary care and performance optimization clinics in the UK and Middle East, including Dubai’s first concierge primary care practice. At Skai, he continues his lifelong mission: translating cutting-edge biotechnology and complex biological data into clear, actionable medical decisions that help individuals remain sharper, stronger, and healthier for longer.
Dr. McAllister also brings an unparalleled level of scientific credibility to this emerging field. His pioneering work in cell-based therapies was recognized by Scientific American as one of the Top 50 achievements in science, business, and policy, and he has twice been named a finalist for the prestigious NIH Pioneer Award. His scientific work has been widely published and reviewed in the most respected medical and scientific journals, including The New England Journal of Medicine, Lancet, Nature Medicine, and Science. His research has contributed to the clinical understanding of regenerative therapies, translational medicine, and the biological foundations of aging, and he continues to influence both academic discourse and applied clinical practice through his publications and advisory roles.
Dr. McAllister holds a B.S. in Mechanical Engineering from the University of Washington and a PhD in Biomedical Engineering from the University of California, San Diego. Across every phase of his career, he has remained guided by a single principle: predictive insight only becomes powerful when paired with human understanding and continuous care. That belief underpins his enduring impact on healthcare, turning early detection into meaningful action, and longevity science into everyday clinical reality.
